onyx, I agree there is a lot to be optimistic about with this...

onyx, I agree there is a lot to be optimistic about with this company, they have done the hard yards getting their product accepted on the world market. One of the frustrations seems to be the long lead times between small scale testing of the product through to actual sales, although as the company says that is improving in Europe and should presumably elsewhere as the word spreads of the product's efficacy.

I'd like to hear more about their outlook for cashflow in the next couple of quarters. The last page comment was not encouraging. The company had $463k in cash at at June 30, that has deteriorated to approx $350 in less than 2 months. Cash receipts can be lumpy in this type of business so the decline may mean nothing or it could mean continued cash drain. Hopefully next week's final report will clear things up.